Edwards Lifesciences (EW) Change in Accured Expenses (2009 - 2026)

Edwards Lifesciences' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$347.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 235.69% year-over-year to -$347.1 million in Q1 2026; TTM through Mar 2026 was $151.4 million, a 101.33% increase from a year earlier, with the FY2025 full-year figure at $395.1 million, up 341.45% from the prior year.
• Change in Accured Expenses fell to -$347.1 million in Q1 2026 per EW's latest filing, from $168.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $226.1 million in Q3 2025 and bottomed at -$347.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $29.9 million (2024), against an average of $15.4 million.
• Across the five-year window, Change in Accured Expenses slumped 1074.19% in 2022 and jumped 5541.94% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $34.3 million in 2022, then retreated by 2.62% to $33.4 million in 2023, then plunged by 109.28% to -$3.1 million in 2024, then soared by 5541.94% to $168.7 million in 2025, then tumbled by 305.75% to -$347.1 million in 2026.
• Per Business Quant, the three latest EW Change in Accured Expenses figures stand at -$347.1 million (Q1 2026), $168.7 million (Q4 2025), and $226.1 million (Q3 2025).